BridgeBio prices $250M public offering at $29.00/share; funds acoramidis launch and pipeline

BridgeBio Pharma, Inc.

8,620,690 shares priced at $29.00; underwriters have 30-day option for 1,293,103 additional shares.
Net proceeds estimated at ~$250M; expected to fund operations into H2 2026.
Proceeds to support commercial launch of acoramidis, if approved, and clinical/preclinical development.
Offering expected to close March 8, 2024; 60-day lock-up for directors and officers.
J.P. Morgan, Cantor Fitzgerald, Mizuho act as joint book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters
Value: approximately $250.0 million
Effective: 2024-03-05

Exact text from the filing

On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-011766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.